Literature DB >> 1715292

Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

E Rønne1, N Behrendt, V Ellis, M Ploug, K Danø, G Høyer-Hansen.   

Abstract

We have raised four monoclonal antibodies recognizing different epitopes within the human cell-surface receptor for urokinase-type plasminogen activator (u-PA). One of these antibodies completely abolishes the potentiation of plasmin generation observed upon incubation of the zymogens pro-u-PA and plasminogen with U937 cells. This antibody, which is also the only one to completely inhibit the binding of DFP-inactivated [125I]-u-PA to U937 cells, is directed against the u-PA binding NH2-terminal domain of u-PAR, a well-defined fragment formed by limited chymotrypsin digestion of purified u-PAR, demonstrating the functional independence of the u-PA binding domain as well as the critical role of u-PAR in the assembly of the cell-surface plasminogen activation system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715292     DOI: 10.1016/0014-5793(91)81042-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

2.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

3.  Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression.

Authors:  N K Rao; G P Shi; H A Chapman
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

4.  Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta.

Authors:  Julia Kiyan; Roman Kiyan; Hermann Haller; Inna Dumler
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

5.  Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.

Authors:  E Bianchi; E Ferrero; F Fazioli; F Mangili; J Wang; J R Bender; F Blasi; R Pardi
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

6.  Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Authors:  Henrik Gårdsvoll; Benedikte Jacobsen; Mette C Kriegbaum; Niels Behrendt; Lars Engelholm; Søren Østergaard; Michael Ploug
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

7.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

9.  Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.

Authors:  F Vilhardt; M Nielsen; K Sandvig; B van Deurs
Journal:  Mol Biol Cell       Date:  1999-01       Impact factor: 4.138

10.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.